A Phase 3 interventional study of Fluticasone Furoate/Vilanterol and Vilanterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 72 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 4th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 446 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 25 interventional studies. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 25 have an industry lead sponsor. The 5 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 66th largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 114th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
1 of the studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled corticosteroid/long acting beta-agonist
Drug: Fluticasone Furoate/Vilanterol
Inhaled long acting beta-agonist
Drug: Vilanterol
Placebo
Drug: Placebo
Drug pages: Fluticasone furoate · Vilanterol
Inhaled corticosteroid/long acting beta-agonist
Inhaled long acting beta-agonist
Placebo
Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)
PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of (Eh/2ρR), where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and ρ is the blood density. Change from BL was calculated as the Day 168 value minus the BL value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking history, history of exacerbation strata, geographical region, BL aPWV and interaction terms of BL by visit and treatment by visit.
Time frame: BL to Day 168
Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry at Screening, Days 1, 28, 84, 126, and 168. BL FEV1 was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 was defined as the mean of the FEV1 values obtained 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was preformed using a repeated measures model with covariates of visit, treatment, history of exacerbation strata, geographical region, BL FEV1 and interaction terms of BL by visit and treatment by visit.
Time frame: BL to Day 168
Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period
Participants were given daily record cards for daily completion from BL (Week -1) through Week 24 (Visit 6) each morning and prior to taking study medication (i.e., single-blind and double-blind study medication) supplemental medication (albuterol \[salbutamol\] if received) and ipratropium bromide (if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Analysis was performed using an analysis of covarience (ANCOVA) model with covariates of treatment, BL mean of occasions of rescue medication use (Week -1), history of exacerbation, and geographical region.
Time frame: BL (Week -1), Week 1 to Week 24
A total of 3011 participants (par.) were screened, 559 entered the Run-in Period (RIP), of whom 444 were randomized and received at least one dose of study medication; 430 of these were included in the Intent-to-Treat (ITT) Population.
| Milestone | Placebo-Run-in | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|---|
| Started | 559 | 0 | 0 | 0 |
| Completed | 444 | 0 | 0 | 0 |
| Not completed | 115 | 0 | 0 | 0 |
| Withdrew: Did not meet continuation criteria | 102 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 |
| Milestone | Placebo-Run-in | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|---|
| Started | 0 | 141 | 154 | 135 |
| Completed the treatment period | 0 | 96 | 124 | 110 |
| Completed | 0 | 97 | 124 | 111 |
| Not completed | 0 | 44 | 30 | 24 |
| Withdrew: Adverse event | 0 | 8 | 6 | 7 |
| Withdrew: Lack of efficacy-no sub-reason | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy-sub-reason exacerbation | 0 | 13 | 13 | 6 |
| Withdrew: Protocol violation | 0 | 4 | 3 | 3 |
| Withdrew: Protocol-defined stopping criteria | 0 | 4 | 3 | 6 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 |
| Withdrew: Physician decision | 0 | 3 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 7 | 4 | 1 |
PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of (Eh/2ρR), where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and ρ is the blood density. Change from BL was calculated as the Day 168 value minus the BL value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking history, history of exacerbation strata, geographical region, BL aPWV and interaction terms of BL by visit and treatment by visit.
| meters per second (m/sec) | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|
| Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168) | -1.97 ± 0.279 | -1.95 ± 0.241 | -1.75 ± 0.256 |
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry at Screening, Days 1, 28, 84, 126, and 168. BL FEV1 was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 was defined as the mean of the FEV1 values obtained 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was preformed using a repeated measures model with covariates of visit, treatment, history of exacerbation strata, geographical region, BL FEV1 and interaction terms of BL by visit and treatment by visit.
| Liters (L) | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|
| Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168 | -0.049 ± 0.0221 | 0.033 ± 0.0202 | 0.106 ± 0.0210 |
Participants were given daily record cards for daily completion from BL (Week -1) through Week 24 (Visit 6) each morning and prior to taking study medication (i.e., single-blind and double-blind study medication) supplemental medication (albuterol \[salbutamol\] if received) and ipratropium bromide (if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Analysis was performed using an analysis of covarience (ANCOVA) model with covariates of treatment, BL mean of occasions of rescue medication use (Week -1), history of exacerbation, and geographical region.
| Occasions per 24 hours | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|
| Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period | 1.97 ± 0.093 | 1.50 ± 0.089 | 1.47 ± 0.095 |
Collected over On-treatment serious adverse events (SAE) and non-serious AEs were collected from the start of the double-blind (DB) treatment period (Visit 2) through the follow-up contact (7 days after Visit 6 [Week 25]).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QD | — | 5/145 (3.4%) | 24/145 (16.6%) |
| VI 25 µg QD | — | 12/158 (7.6%) | 27/158 (17.1%) |
| FF/VI 100/25 µg QD | — | 9/141 (6.4%) | 34/141 (24.1%) |
| Event | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/145 | 5/158 | 2/141 |
| PneumoniaInfections and infestations | 2/145 | 1/158 | 2/141 |
| FaecalomaGastrointestinal disorders | 0/145 | 0/158 | 1/141 |
| PyelonephritisInfections and infestations | 0/145 | 0/158 | 1/141 |
| Fibula fractureInjury, poisoning and procedural complications | 0/145 | 0/158 | 1/141 |
| Hip fractureInjury, poisoning and procedural complications | 0/145 | 0/158 | 1/141 |
| Tibia fractureInjury, poisoning and procedural complications | 0/145 | 0/158 | 1/141 |
| Hepatic enzyme increasedInvestigations | 0/145 | 0/158 | 1/141 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 0/158 | 1/141 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/145 | 0/158 | 1/141 |
| Event | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/145 | 12/158 | 9/141 |
| Oral candidiasisInfections and infestations | 1/145 | 2/158 | 9/141 |
| HeadacheNervous system disorders | 5/145 | 9/158 | 8/141 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/145 | 2/158 | 6/141 |
| Upper respiratory tract infectionInfections and infestations | 6/145 | 4/158 | 2/141 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/145 | 1/158 | 5/141 |
| Back painMusculoskeletal and connective tissue disorders | 5/145 | 5/158 | 4/141 |
| Age, Continuous(Years) | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD | Total |
|---|---|---|---|---|
| Mean | 68.2 ± 8.10 | 68.7 ± 7.69 | 68.5 ± 8.01 | 68.5 ± 7.91 |
| Sex: Female, Male(Participants) | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD | Total |
|---|---|---|---|---|
| Female | 22 | 36 | 31 | 89 |
| Male | 119 | 118 | 104 | 341 |
| Race/Ethnicity, Customized(Participants) | Placebo QD | VI 25 µg QD | FF/VI 100/25 µg QD | Total |
|---|---|---|---|---|
| African American/African Heritage | 7 | 4 | 6 | 17 |
| Asian - Central/South Asian Heritage | 1 | 0 | 0 | 1 |
| Asian - East Asian Heritage | 21 | 23 | 18 | 62 |
| Asian - South East Asian Heritage | 45 | 51 | 47 | 143 |
| Asian - Mixed Race | 1 | 0 | 0 | 1 |
| White - Arabic/North African Heritage | 1 | 1 | 0 | 2 |
| White - White/Caucasian/European Heritage | 64 | 75 | 64 | 203 |
| Mixed Race | 1 | 0 | 0 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Mar 2011 to primary completion in Nov 2014, 44 months.
Results were first posted in Jul 2015, 8 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 44 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol
Pulmonary Disease, Chronic Obstructive →